Equity Profile

ACLX

Arcellx, Inc.

Health CareBiotechnology$6.7B

May7Thu

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EDT

Company Snapshot

Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

-1.02

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACLX Q1-2026 Earnings Preview

Context

Company Snapshot

Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating in the health care sector, Arcellx aims to address unmet medical needs with its proprietary technology, which is crucial as the demand for effective cancer therapies continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-36.35%

Avg Stock Reaction

+2.14%

Last Quarter Recap

In Q4-2025, Arcellx reported a significant earnings miss with an EPS of -4.07, far below the expected -1.00. The stock reacted slightly positively the next day, indicating some investor optimism despite the disappointing results.

Management Promises & Guidance

Focus on cost management to improve future profitability.
Commitment to advancing clinical trials for their therapies.
Plans to enhance communication with investors regarding future strategies.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Arcellx's upcoming earnings, expecting a modest improvement in revenue and a narrower loss per share compared to previous quarters.

Bull Case

If Arcellx can exceed revenue expectations and show progress in its clinical trials, it could signal strong future growth potential, attracting more investor interest.

Bear Case

Conversely, if the company fails to meet revenue targets or provides weak guidance, it could lead to further declines in investor confidence and stock price.

Key Metrics to Watch

EPS

-1.02

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the revenue exceed the consensus estimate of $6M?

Revenue performance is critical for assessing the company's market traction and future growth prospects.

What specific progress has been made in clinical trials?

Updates on clinical trials can significantly impact investor sentiment and the company's valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Arcellx's potential for revenue growth due to recent advancements in their clinical programs.

Supporting Evidence

The company has a history of surprising on the upside, with a 50% EPS beat rate.

Recent clinical trial results have shown promise, which could translate into higher revenue than anticipated.

Key Risk

If the revenue comes in below $4M, it could undermine confidence in the company's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could indicate the company's ability to recover from previous misses and regain investor confidence.

Bull Confirmed If

Revenue growth exceeding $6M and a narrower EPS loss than -1.02 would confirm the bull case.

Bear Confirmed If

Revenue falling below $4M or an EPS loss greater than -1.02 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±0.52%

Historical Avg

±2.3%

Pricing cheap

The options market is pricing in a small move, suggesting that investors are not anticipating significant volatility around the earnings report.

Options are pricing ±0.5% while ACLX has averaged ±2.3% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcellx beats expectations, history suggests the stock could rise by an average of +2.88%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with history suggesting an average drop of -1.40% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and their expected timelines.
2Any commentary on cost management strategies and their impact on future profitability.
3Insights into market demand for Arcellx's therapies and any new partnerships.
4Guidance on future revenue expectations and how the company plans to achieve them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

BSMReported

Black Stone Minerals, L.P.

RecapView

May4

FOLDAMC

Company Snapshot

Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

-1.02

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACLX Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-36.35%

Avg Stock Reaction

+2.14%

Last Quarter Recap

Management Promises & Guidance

Focus on cost management to improve future profitability.
Commitment to advancing clinical trials for their therapies.
Plans to enhance communication with investors regarding future strategies.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Arcellx's upcoming earnings, expecting a modest improvement in revenue and a narrower loss per share compared to previous quarters.

Bull Case

If Arcellx can exceed revenue expectations and show progress in its clinical trials, it could signal strong future growth potential, attracting more investor interest.

Bear Case

Conversely, if the company fails to meet revenue targets or provides weak guidance, it could lead to further declines in investor confidence and stock price.

Key Metrics to Watch

EPS

-1.02

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the revenue exceed the consensus estimate of $6M?

Revenue performance is critical for assessing the company's market traction and future growth prospects.

What specific progress has been made in clinical trials?

Updates on clinical trials can significantly impact investor sentiment and the company's valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Arcellx's potential for revenue growth due to recent advancements in their clinical programs.

Supporting Evidence

The company has a history of surprising on the upside, with a 50% EPS beat rate.

Recent clinical trial results have shown promise, which could translate into higher revenue than anticipated.

Key Risk

If the revenue comes in below $4M, it could undermine confidence in the company's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could indicate the company's ability to recover from previous misses and regain investor confidence.

Bull Confirmed If

Revenue growth exceeding $6M and a narrower EPS loss than -1.02 would confirm the bull case.

Bear Confirmed If

Revenue falling below $4M or an EPS loss greater than -1.02 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±0.52%

Historical Avg

±2.3%

Pricing cheap

The options market is pricing in a small move, suggesting that investors are not anticipating significant volatility around the earnings report.

Options are pricing ±0.5% while ACLX has averaged ±2.3% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcellx beats expectations, history suggests the stock could rise by an average of +2.88%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with history suggesting an average drop of -1.40% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and their expected timelines.
2Any commentary on cost management strategies and their impact on future profitability.
3Insights into market demand for Arcellx's therapies and any new partnerships.
4Guidance on future revenue expectations and how the company plans to achieve them.